Showing 71-75 of 97 :
Three Use Cases For Real-World Data & Artificial Intelligence For Devices And Diagnostics

SEPTEMBER 15, 2021 By Joseph Zabinski, PhD, Senior Director of AI & Precision Medicine, OM1 As innovation in devices and diagnostics accelerates, research approaches and outcomes programs also need to advance to support these developments with high-quality evidence.  At the same time, demonstrating the effectiveness of a device can be challenging because outcomes depend highly[…]

Dell Medical School helps develop artificial intelligence tool for knee surgery

April 2, 2021 – Austin American-Statesman Read the Full Article >> If you had osteoarthritis in your knee, how would you know when it’s the right time to have knee replacement surgery? Dell Medical School at the University of Texas helped patients at UT Health Austin’s Musculoskeletal Institute answer that question by studying a new artificial intelligence tool[…]

Validation Of A Machine Learning Approach To Estimate Systemic Lupus Erythematosus Disease Activity Index Score Categories And Application In A Real-World Dataset

BMJ Journals Published: May 20, 2021 Read the Full Manuscript >>  Objective Use of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in routine clinical practice is inconsistent, and availability of clinician-recorded SLEDAI scores in real-world datasets is limited. This study aimed to validate a machine learning model to estimate SLEDAI score categories using clinical notes[…]

OM1 Launches Multiple Sclerosis Registry With More Than 20,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, July 14, 2021 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its multiple sclerosis (MS) registry. MS is an auto-immune, inflammatory disease that attacks the central nervous system (CNS) and causes a variety of neurological symptoms, such as muscle weakness, spasticity, fatigue, numbness, vision[…]

OM1 Rheumatoid Arthritis Registry Reaches More Than 200,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, April 20, 2021 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, announced its Rheumatoid Arthritis (RA) registry now includes longitudinal clinical data from rheumatology specialists on more than 200,000 patients. OM1 also offers other specialty rheumatology registries, including Juvenile Idiopathic Arthritis (JIA), which has deep[…]